Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid symbols : FNCTF save search
BioLink Life Sciences, Charak Foundation and KARE Biosciences Announce contract for developing a novel treatment of COVID pneumonia and prevention of long COVID
Published: 2022-10-05 (Crawled : 22:00) - prnewswire.com
FNCTF | News | $11.16 130
|
Communications
|
| O: 4.3%
H: 0.0%
C: -9.09%
treatment covid life contract
The REMM Group Designs Their New Orange County Corporate Headquarters for the Post COVID Work Style
Published: 2022-05-24 (Crawled : 20:00) - prnewswire.com
FNCTF | News | $11.16 130
|
Communications
| Email alert
Add to watchlist
covid work group designation
Citrus Phytochemicals & Long COVID Recovery Study
Published: 2022-04-14 (Crawled : 17:00) - limoneira.com
LMNR 4 | $19.9 0.96% 8.5K
|
Process Industries
|
| O: 0.22%
H: 2.03%
C: 0.51%
covid citrus
Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults
Published: 2022-03-15 (Crawled : 23:00) - globenewswire.com
PFE | News A | $26.34 0.31% 7.7M
|
Health Technology
|
| O: 0.56%
H: 0.0%
C: 0.0%
SNY | News | $47.5 0.74% 450K
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
BNTX | News | $89.015 1.14% 120K
|
Health Technology
|
| O: 1.63%
H: 11.55%
C: 11.21%
covid-19 covid authorization vaccine tiona merge order emergency use authorization
Merck and Ridgeback Announce That 3.1 Million Courses of Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Have Been Supplied to the U.S. Government for Use in the United States
Published: 2022-02-08 (Crawled : 12:00) - biospace.com/
MRK | $127.065 0.1% 2.2M
|
Health Technology
|
| O: -2.14%
H: 0.3%
C: -0.25%
covid-19 state covid molnupiravir antiviral
Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies
Published: 2022-01-28 (Crawled : 12:30) - biospace.com/
MRK | $127.065 0.1% 2.2M
|
Health Technology
|
| O: -1.29%
H: 1.82%
C: 1.71%
covid-19 covid molnupiravir antiviral in vitro
Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine
Published: 2022-01-18 (Crawled : 13:00) - biospace.com/
FNCTF | News | $11.16 130
|
Communications
|
| O: -0.4%
H: 0.0%
C: -0.58%
MRK | $127.065 0.1% 2.2M
|
Health Technology
|
| O: -0.37%
H: 0.0%
C: 0.0%
covid-19 covid molnupiravir antiviral
Beyond COVID-19: the Potential of mRNA in Occupational Cancer
Published: 2022-01-13 (Crawled : 13:00) - biospace.com/
FNCTF | News | $11.16 130
|
Communications
| Email alert
Add to watchlist
covid-19 covid potential cancer
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older
Published: 2022-01-03 (Crawled : 18:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
PFE | News A | $26.34 0.31% 7.7M
|
Health Technology
|
| O: -0.93%
H: 0.09%
C: -3.16%
SNY | News | $47.5 0.74% 450K
|
Health Technology
|
| O: 1.16%
H: 0.0%
C: 0.0%
BNTX | News | $89.015 1.14% 120K
|
Health Technology
|
| O: -1.52%
H: 0.89%
C: -8.67%
covid-19 fda als covid authorization vaccine merge order emergency use authorization
Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan
Published: 2021-12-24 (Crawled : 14:00) - biospace.com/
MRK | $127.065 0.1% 2.2M
|
Health Technology
| Email alert
Add to watchlist
FNCTF | News | $11.16 130
|
Communications
| Email alert
Add to watchlist
covid-19 treatment approval covid molnupiravir antiviral merge
Top DevOps Services and Popular Tools at GoodFirms Assist Businesses in Faster Software Development Cycle During Covid-19
Published: 2021-12-14 (Crawled : 09:00) - prnewswire.com
FNCTF | News | $11.16 130
|
Communications
|
| O: 1.65%
H: 0.0%
C: -1.39%
covid-19 covid software
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older
Published: 2021-12-09 (Crawled : 18:00) - globenewswire.com
FNCTF | News | $11.16 130
|
Communications
|
| O: 0.69%
H: 0.68%
C: 0.68%
PFE | News A | $26.34 0.31% 7.7M
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
SNY | News | $47.5 0.74% 450K
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
BNTX | News | $89.015 1.14% 120K
|
Health Technology
|
| O: -3.53%
H: 0.32%
C: -4.65%
covid-19 fda covid authorization vaccine merge order emergency use authorization
Follow-Up Data from Phase 3 Trial Of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
Published: 2021-11-22 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: -0.23%
PFE | News A | $26.34 0.31% 7.7M
|
Health Technology
|
| O: -1.72%
H: 1.02%
C: 0.49%
SNY | News | $47.5 0.74% 450K
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
BNTX | News | $89.015 1.14% 120K
|
Health Technology
|
| O: 7.04%
H: 8.12%
C: 7.96%
covid vaccine phase 3 trial
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older
Published: 2021-11-19 (Crawled : 13:30) - globenewswire.com
FNCTF | News | $11.16 130
|
Communications
|
| O: -2.67%
H: 0.45%
C: 0.45%
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 3.28%
H: 0.0%
C: 0.0%
PFE | News A | $26.34 0.31% 7.7M
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
SNY | News | $47.5 0.74% 450K
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
BNTX | News | $89.015 1.14% 120K
|
Health Technology
|
| O: 1.58%
H: 0.0%
C: 0.0%
covid fda vaccine merge order emergency use authorization
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years
Published: 2021-10-29 (Crawled : 22:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
PFE | News A | $26.34 0.31% 7.7M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.5 0.74% 450K
|
Health Technology
| Email alert
Add to watchlist
FNCTF | News | $11.16 130
|
Communications
| Email alert
Add to watchlist
BNTX | News | $89.015 1.14% 120K
|
Health Technology
| Email alert
Add to watchlist
covid fda children vaccine merge emergency use authorization
OBHealthy and Dr. Ernest Rogers Creates Webinar to Address COVID-19 Concerns for Pets
Published: 2021-09-10 (Crawled : 13:00) - prnewswire.com
FNCTF | News | $11.16 130
|
Communications
| Email alert
Add to watchlist
covid pets covid-19
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.595 164.08% 13M
|
AGBA | $2.355 88.4% 34M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.75 79.52% 1.5M
|
MTC | $2.28 46.15% 2.6M
|
Technology Services
OPRT | News | $3.14 39.56% 7.6M
|
Finance
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.865 33.21% 2.4M
|
n/a
PALI | $6.37 29.21% 21M
|
Manufacturing
LOCL | $3.33 27.59% 43K
|
Your saved searches
Save your searches and get alerts when important news are released.